Yonsei Med J.  2007 Feb;48(1):35-40. 10.3349/ymj.2007.48.1.35.

Syringoma: A Clinicopathologic and Immunohistologic Study and Results of Treatment

• Lee JH
• Chang JY
• Lee KH

• KMID: 1093521
• DOI: http://doi.org/10.3349/ymj.2007.48.1.35

Abstract

The purpose of our study was to describe clinical and histopathological features of sixty one patients with histological diagnosis of syringoma over four year period in our dermatology clinic in Korea. Female:male ratio was 6.6:1 with onset of age during 2nd and 3rd decades in more than half of the patients in our study. The most frequently involved site was eyelids (43 cases, 70.5%) and the most common color of lesion was skin-color (30 cases, 49.2%). In 34 cases, characteristic tad-pole appearances (55.7%) were observed. Basal hyperpigmentation was observed more frequently in brown-colored lesion (p=0.005). Fibrosis was observed more frequently in erythematous lesion (p=0.033). Keratin cyst was observed less frequently in genital involved group (p=0.006). We also performed immunohistochemical stain for the presence of progesterone receptor (PR) and estrogen receptor (ER) in fifty six cases with negative results.

Keyword

Syringoma; immunohistochemical staining; treatment

Figure

• 

  Fig. 1 Age of onset distribution of 61 cases of syringoma patients shows two peaks in 3rd and 5th decades.

Reference

1. Elder D, Elenitsas R, Jaworsky C, Johnson B Jr. Lever's histopathology of the skin. 1997. 8th ed. Philadelphia: JB Lippincott;778–779.

2. Butterworth T, Strean LP, Beerman H, Wood MG. Syringoma and mongolism. Arch Dermatol. 1964. 90:482–487.

3. Patrizi A, Neri I, Marzaduri S, Varotti E, Passarini B. Syringoma: a review of twenty-nine cases. Acta Derm Venereol. 1998. 78:460–462.

4. Furue M, Hori Y, Nakabayashi Y. Clear-cell syringoma. Association with diabetes mellitus. Am J Dermatopathol. 1984. 6:131–138.

5. Berbis P, Fabre JF, Jancovici E, Privat Y, Benderitter T. Late-onset syringomas of the upper extremities associated with a carcinoid tumor. Arch Dermatol. 1989. 125:848–849.

6. Huang YH, Chuang YH, Kuo TT, Yang LC, Hong HS. Vulvar syringoma: a clinicopathologic and immunohistologic study of 18 patients and results of treatment. J Am Acad Dermatol. 2003. 48:735–739.

7. Sanchez TS, Dauden E, Casas AP, Garcia-Diez A. Eruptive pruritic syringomas: treatment with topical atropine. J Am Acad Dermatol. 2001. 44:148–149.

8. Trager JD, Silvers J, Reed JA, Scott RA. Neck and vulvar papules in an 8-year-old girl. Arch Dermatol. 1999. 135:203–206.

9. Friedman SJ, Butler DF. Syringoma presenting as milia. J Am Acad Dermatol. 1987. 16:310–314.

10. Soler-Carrillo J, Estrach T, Mascaro JM. Eruptive syringoma: 27 new cases and review of the literature. J Eur Acad Dermatol Venereol. 2001. 15:242–246.

11. Frazier CC, Camacho AP, Cockerell CJ. The treatment of eruptive syringomas in an African American patient with a combination of trichloroacetic acid and CO₂ laser destruction. Dermatol Surg. 2001. 27:489–492.

12. Iwao F, Onozuka T, Kawashima T. Vulval syringoma successfully treated with tranilast. Br J Dermatol. 2005. 153:1228–1230.

13. Wallace ML, Smoller BR. Progesterone receptor positivity supports hormonal control of syringomas. J Cutan Pathol. 1995. 22:442–445.

14. Yorganci A, Kale A, Dunder I, Ensari A, Sertcelik A. Vulvar syringoma showing progesterone receptor positivity. BJOG. 2000. 107:292–294.

15. Timpanidis PC, Lakhani SR, Groves RW. Progesterone receptor-positive eruptive syringoma associated with diabetes. J Am Acad Dermatol. 2003. 48:103–104.

16. Bal N, Aslan E, Kayaselcuk F, Tarim E, Tuncer I. Vulvar syringoma aggravated by pregnancy. Pathol Oncol Res. 2003. 9:196–197.